{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T10:22:17Z","timestamp":1792664537894,"version":"4.5.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Neurol"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1007\/s11940-020-0610-1","type":"journal-article","created":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T03:02:51Z","timestamp":1580353371000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Therapy in Sleep-Related Hypermotor Epilepsy (SHE)"],"prefix":"10.1007","volume":"22","author":[{"given":"Gian Maria","family":"Asioli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Bisulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Licchetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Tinuper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Provini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,30]]},"reference":[{"issue":"2","key":"610_CR1","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/sleep\/4.2.129","volume":"4","author":"E Lugaresi","year":"1981","unstructured":"Lugaresi E, Cirignotta F. Hypnogenic paroxysmal dystonia : epileptic seizure or a new syndrome ? Sleep. 1981;4(2):129\u201338.","journal-title":"Sleep."},{"issue":"5","key":"610_CR2","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1528-1157.1990.tb06105.x","volume":"31","author":"P Tinuper","year":"1990","unstructured":"Tinuper P, Cerullo A, Cirignotta F, Cortelli P, Lugaresi E, Montagna P. Nocturnal paroxysmal dystonia with short-lasting attacks: three cases with evidence for an epileptic frontal lobe origin of seizures. Epilepsia. 1990;31(5):549\u201356.","journal-title":"Epilepsia."},{"issue":"19","key":"610_CR3","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1212\/WNL.0000000000002666","volume":"86","author":"P Tinuper","year":"2016","unstructured":"\u2022\u2022 Tinuper P, Bisulli F, Cross JH, Hesdorffer D, Kahane P, Nobili L, et al. Definition and diagnostic criteria of sleep-related hypermotor epilepsy. Neurology. 2016;86(19):1834\u201342. The paper summarized the results of the Consensus Conference held in Bologna, Italy in 2014 on SHE during which the Nocturnal Frontal Lobe Epilepsy was renamed Sleep-Related Hypermotor Epilepsy (SHE). Major points of agreement emerged on the relationship of the seizures with sleep and not with the circadian pattern of seizure occurrence and on the possible extrafrontal origin of hypermotor seizures. Diagnostic criteria with different level of certainty are also provided.","journal-title":"Neurology"},{"key":"610_CR4","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.seizure.2016.11.023","volume":"44","author":"Paolo Tinuper","year":"2017","unstructured":"Tinuper P, Bisulli F. From nocturnal frontal lobe epilepsy to sleep-related hypermotor epilepsy: a 35-year diagnostic challenge. Seizure. 2017;44:87\u201392.","journal-title":"Seizure"},{"key":"610_CR5","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1212\/WNL.40.7.1063","volume":"40","author":"P Montagna","year":"1990","unstructured":"Montagna P, Sforza E, Tinuper P, Cirignotta F, Lugaresi E. Paroxysmal arousals during sleep. Neurology. 1990;40:1063\u20136.","journal-title":"Neurology"},{"issue":"3","key":"610_CR6","doi-asserted-by":"crossref","first-page":"479","DOI":"10.5665\/sleep.4514","volume":"38","author":"L Vignatelli","year":"2015","unstructured":"Vignatelli L, Bisulli F, Giovannini G, Licchetta L, Naldi I. Prevalence of nocturnal frontal lobe epilepsy in the adult population of Bologna and Modena, Emilia Romagna region. Italy Sleep. 2015;38(3):479\u201385.","journal-title":"Italy Sleep"},{"issue":"6","key":"610_CR7","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1093\/brain\/122.6.1017","volume":"122","author":"F Provini","year":"1999","unstructured":"\u2022\u2022 Provini F, Plazzi G, Tinuper P, Vandi S, Lugaresi E, Montagna P. Nocturnal frontal lobe epilepsy: a clinical and polygraphic overview of 100 consecutive cases. Brain. 1999;122(6):1017\u201331. The most large series of clinical and polysomnographic data of NFLE including a detailed characterization of the different seizure types that constitute NFLE. In these series, carbamazepine completely abolishes the seizures in approximately 20% of the cases and gives remarkable relief (reduction of the seizures by at least 50%) in another 48%.","journal-title":"Brain"},{"issue":"8896","key":"610_CR8","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0140-6736(94)91463-X","volume":"343","author":"IE Scheffer","year":"1994","unstructured":"Scheffer IE, Bhatia KP, Lopes-Cendes I, Fish DR, Marsden CD, Andermann F, et al. Autosomal dominant frontal epilepsy misdiagnosed as sleep disorder. Lancet. 1994;343(8896):515\u20137.","journal-title":"Lancet."},{"key":"610_CR9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphys.2015.00022","volume":"6","author":"A Becchetti","year":"2015","unstructured":"Becchetti A, Aracri P, Meneghini S, Brusco S, Amadeo A. The role of nicotinic acetylcholine receptors in autosomal dominant nocturnal frontal lobe epilepsy. Front Physiol. 2015;6:1\u201313.","journal-title":"Front Physiol"},{"issue":"4","key":"610_CR10","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.smrv.2005.12.004","volume":"10","author":"L Parrino","year":"2006","unstructured":"Parrino L, Halasz P, Tassinari CA, Terzano MG. CAP, epilepsy and motor events during sleep: the unifying role of arousal. Sleep Med Rev. 2006;10(4):267\u201385.","journal-title":"Sleep Med Rev"},{"issue":"11","key":"610_CR11","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1038\/ng.2440","volume":"44","author":"SE Heron","year":"2012","unstructured":"Heron SE, Smith KR, Bahlo M, Nobili L, Kahana E, Licchetta L, et al. Missense mutations in the sodium-gated potassium channel gene KCNT1 cause severe autosomal dominant nocturnal frontal lobe epilepsy. Nat Genet. 2012;44(11):1188\u201390.","journal-title":"Nat Genet"},{"issue":"4","key":"610_CR12","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/ana.24128","volume":"75","author":"CJ Milligan","year":"2014","unstructured":"Milligan CJ, Li M, Gazina EV, Heron SE, Nair U, Trager C, et al. KCNT1 gain of function in 2 epilepsy phenotypes is reversed by quinidine. Ann Neurol. 2014;75(4):581\u201390.","journal-title":"Ann Neurol"},{"issue":"1","key":"610_CR13","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1212\/WNL.0000000000003459","volume":"88","author":"L Licchetta","year":"2017","unstructured":"\u2022\u2022 Licchetta L, Bisulli F, Di VL, Mostacci B, Rinaldi C, Trippi I. Sleep-related hypermotor epilepsy long-term outcome in a large cohort. Neurology. 2017;88(1):70\u20137. The paper reported the poor prognosis of SHE analysing 139 patients with a 16-year median follow-up.","journal-title":"Neurology"},{"issue":"SUPPL. 5","key":"610_CR14","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1528-1167.2006.00882.x","volume":"47","author":"L Vignatelli","year":"2006","unstructured":"Vignatelli L, Bisulli F, Naldi I, Ferioli S, Pittau F, Provini F, et al. Excessive daytime sleepiness and subjective sleep quality in patients with nocturnal frontal lobe epilepsy: a case-control study. Epilepsia. 2006;47(SUPPL. 5):73\u20137.","journal-title":"Epilepsia."},{"key":"610_CR15","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.sleep.2018.03.027","volume":"48","author":"L Licchetta","year":"2018","unstructured":"Licchetta L, Poda R, Vignatelli L, Pippucci T, Zenesini C, Menghi V, et al. Profile of neuropsychological impairment in sleep-related hypermotor epilepsy. Sleep Med. 2018;48:8\u201315.","journal-title":"Sleep Med"},{"issue":"5","key":"610_CR16","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.pediatrneurol.2007.06.013","volume":"37","author":"GP Raju","year":"2007","unstructured":"Raju GP, Sarco DP, Poduri A, Riviello JJ, Bergin AMR, Takeoka M. Oxcarbazepine in children with nocturnal frontal-lobe epilepsy. Pediatr Neurol. 2007;37(5):345\u20139.","journal-title":"Pediatr Neurol"},{"issue":"8","key":"610_CR17","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.seizure.2006.07.002","volume":"15","author":"A Oldani","year":"2006","unstructured":"Oldani A, Manconi M, Zucconi M, Martinelli C, Ferini-Strambi L. Topiramate treatment for nocturnal frontal lobe epilepsy. Seizure. 2006;15(8):649\u201352.","journal-title":"Seizure."},{"issue":"9","key":"610_CR18","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1046\/j.1528-1157.2003.58102.x-i1","volume":"44","author":"JO Willoughby","year":"2003","unstructured":"Willoughby JO, Pope KJ, Eaton V. Nicotine as an antiepileptic agent in ADNFLE: an N-of-one study. Epilepsia. 2003;44(9):1238\u201340.","journal-title":"Epilepsia."},{"issue":"1","key":"610_CR19","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1212\/WNL.0000000000004769","volume":"90","author":"SA Mullen","year":"2018","unstructured":"Mullen SA, Carney PW, Roten A, Ching M, Lightfoot PA, Churilov L, et al. Precision therapy for epilepsy due to KCNT1 mutations: a randomized trial of oral quinidine. Neurology. 2018;90(1):e67\u201372.","journal-title":"Neurology."},{"issue":"10","key":"610_CR20","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1111\/epi.13863","volume":"58","author":"M Puligheddu","year":"2017","unstructured":"Puligheddu M, Melis M, Pillolla G, Milioli G, Parrino L, Terzano GM, et al. Rationale for an adjunctive therapy with fenofibrate in pharmacoresistant nocturnal frontal lobe epilepsy. Epilepsia. 2017;58(10):1762\u201370.","journal-title":"Epilepsia."},{"issue":"3","key":"610_CR21","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/BF00168560","volume":"352","author":"R Yoshimura","year":"1995","unstructured":"Yoshimura R, Yanagihara N, Terao T, Minami K, Abe K, Izumi F. Inhibition by carbamazepine of various ion channels-mediated catecholamine secretion in cultured bovine adrenal medullary cells. Naunyn Schmiedeberg's Arch Pharmacol. 1995;352(3):297\u2013303.","journal-title":"Naunyn Schmiedeberg's Arch Pharmacol"},{"issue":"Pt 1","key":"610_CR22","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/brain\/118.1.61","volume":"118","author":"IE Scheffer","year":"1995","unstructured":"Scheffer IE, Bhatia KP, Lopes-Cendes I, Fish DR, Marsden CD, Andermann E, et al. Autosomal dominant nocturnal frontal lobe epilepsy. A distinctive clinical disorder. Brain. 1995;118(Pt 1):61\u201373.","journal-title":"Brain."},{"issue":"9","key":"610_CR23","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1111\/j.1528-1157.1999.tb00848.x","volume":"40","author":"F Picard","year":"1999","unstructured":"Picard F, Bertrand S, Steinlein OK, Bertrand D. Mutated nicotinic receptors responsible for autosomal dominant nocturnal frontal lobe epilepsy are more sensitive to carbamazepine. Epilepsia. 1999;40(9):1198\u2013209.","journal-title":"Epilepsia."},{"issue":"1","key":"610_CR24","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ejphar.2010.05.063","volume":"643","author":"C Di Resta","year":"2010","unstructured":"Di Resta C, Ambrosi P, Curia G, Becchetti A. Effect of carbamazepine and oxcarbazepine on wild-type and mutant neuronal nicotinic acetylcholine receptors linked to nocturnal frontal lobe epilepsy. Eur J Pharmacol. 2010;643(1):13\u201320.","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"610_CR25","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2147\/nedt.2006.2.4.475","volume":"2","author":"M Mula","year":"2006","unstructured":"Mula M, Cavanna AE, Monaco F. Psychopharmacology of topiramate: from epilepsy to bipolar disorder. Neuropsychiatr Dis Treat. 2006;2(4):475\u201388.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"610_CR26","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.eplepsyres.2014.11.021","volume":"110","author":"MA Rogawski","year":"2015","unstructured":"Rogawski MA, Tofighy A, White HS, Matagne A, Wolff C. Current understanding of the mechanism of action of the antiepileptic drug lacosamide. Epilepsy Res. 2015;110:189\u2013205.","journal-title":"Epilepsy Res"},{"key":"610_CR27","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.sleep.2015.09.028","volume":"23","author":"C Liguori","year":"2016","unstructured":"Liguori C, Romigi A, Placidi F, Sarpa MG, Mercuri NB, Izzi F. Effective treatment of nocturnal frontal lobe epilepsy with lacosamide: a report of two cases. Sleep Med. 2016;23:121\u20132.","journal-title":"Sleep Med"},{"issue":"5","key":"610_CR28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/jsr.12669","volume":"27","author":"SR Samarasekera","year":"2018","unstructured":"Samarasekera SR, Berkovic SF, Scheffer IE. A case series of lacosamide as adjunctive therapy in refractory sleep-related hypermotor epilepsy (previously nocturnal frontal lobe epilepsy). J Sleep Res. 2018;27(5):1\u20134.","journal-title":"J Sleep Res"},{"issue":"5","key":"610_CR29","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1177\/106002809603000515","volume":"30","author":"WG Reiss","year":"1996","unstructured":"Reiss WG, Oles KS. Acetazolamide in the treatment of seizures. Ann Pharmacother. 1996;30(5):514\u20139.","journal-title":"Ann Pharmacother"},{"issue":"1","key":"610_CR30","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.1528-1157.1989.tb05285.x","volume":"30","author":"KS Oles","year":"1989","unstructured":"Oles KS, Penry JK, Cole DL, Howard G. Use of acetazolamide as an adjunct to carbamazepine in refractory partial seizures. Epilepsia. 1989;30(1):74\u20138.","journal-title":"Epilepsia."},{"issue":"7","key":"610_CR31","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1046\/j.1528-1157.2003.53002.x","volume":"44","author":"S Varadkar","year":"2003","unstructured":"Varadkar S, Duncan JS, Cross JH. Acetazolamide and autosomal dominant nocturnal frontal lobe epilepsy. Epilepsia. 2003;44(7):986\u20137.","journal-title":"Epilepsia."},{"issue":"3","key":"610_CR32","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.yebeh.2006.07.008","volume":"9","author":"E Brodtkorb","year":"2006","unstructured":"Brodtkorb E, Picard F. Tobacco habits modulate autosomal dominant nocturnal frontal lobe epilepsy. Epilepsy Behav. 2006;9(3):515\u201320.","journal-title":"Epilepsy Behav"},{"issue":"1","key":"610_CR33","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1111\/j.1528-1167.2012.03715.x","volume":"54","author":"A Zerem","year":"2013","unstructured":"Zerem A, Nishri D, Yosef Y, Blumkin L, Lev D, Leshinsky-Silver E, et al. Resolution of epileptic encephalopathy following treatment with transdermal nicotine. Epilepsia. 2013;54(1):2012\u20134.","journal-title":"Epilepsia."},{"issue":"1","key":"610_CR34","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.yebeh.2012.10.014","volume":"26","author":"I Naldi","year":"2013","unstructured":"Naldi I, Bisulli F, Vignatelli L, Licchetta L, Pittau F, Di L, et al. Tobacco habits in nocturnal frontal lobe epilepsy. Epilepsy Behav. 2013;26(1):114\u20137.","journal-title":"Epilepsy Behav"},{"issue":"1","key":"610_CR35","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1617-9625-8-8","volume":"8","author":"EJ Mills","year":"2010","unstructured":"Mills EJ, Wu P, Lockhart I, Wilson K, Ebbert JO. Adverse events associated with nicotine replacement therapy (NRT) for smoking cessation. A systematic review and meta-analysis of one hundred and twenty studies involving 177,390 individuals. Tob Induc Dis. 2010;8(1):8.","journal-title":"Tob Induc Dis"},{"key":"610_CR36","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/ana.24598","volume":"79","author":"PF Chong","year":"2016","unstructured":"Chong PF, Nakamura R, Saitsu H, Matsumoto N, Kira R. Ineffective quinidine therapy in early onset epileptic encephalopathy with KCNT1 mutation. Ann Neurol. 2016;79:502\u20133.","journal-title":"Ann Neurol"},{"issue":"6","key":"610_CR37","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1002\/ana.24520","volume":"78","author":"MA Mikati","year":"2015","unstructured":"Mikati MA, Jiang YH, Carboni M, Shashi V, Petrovski S, Spillmann R, et al. Quinidine in the treatment of KCNT1-positive epilepsies. Ann Neurol. 2015;78(6):995\u20139.","journal-title":"Ann Neurol"},{"issue":"5","key":"610_CR38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0064541","volume":"8","author":"M Puligheddu","year":"2013","unstructured":"Puligheddu M, Pillolla G, Melis M, Lecca S, Marrosu F, de Montis MG, et al. PPAR-alpha agonists as novel antiepileptic drugs: preclinical findings. PLoS One. 2013;8(5):e64541.","journal-title":"PLoS One"},{"issue":"1\u20132","key":"610_CR39","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.eplepsyres.2013.08.018","volume":"107","author":"J Yamada","year":"2013","unstructured":"Yamada J, Zhu G, Okada M, Hirose S, Yoshida S, Shiba Y, et al. A novel prophylactic effect of furosemide treatment on autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE). Epilepsy Res. 2013;107(1\u20132):127\u201337.","journal-title":"Epilepsy Res"},{"issue":"45","key":"610_CR40","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/ng.2599","volume":"31","author":"LM Dibbens","year":"2013","unstructured":"Dibbens LM, de Vries B, Donatello S, Heron SE, Hodgson BL, Chintawar S, et al. Mutations in DEPDC5 cause familial focal epilepsy with variable foci. Nat Genet. 2013;31(45):546.","journal-title":"Nat Genet"},{"issue":"5","key":"610_CR41","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/ana.24126","volume":"75","author":"IE Scheffer","year":"2014","unstructured":"Scheffer IE, Heron SE, Regan BM, Mandelstam S, Crompton DE, Hodgson BL, et al. Mutations in mammalian target of rapamycin regulator DEPDC5 cause focal epilepsy with brain malformations. Ann Neurol. 2014;75(5):782\u20137.","journal-title":"Ann Neurol"},{"issue":"23","key":"610_CR42","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1212\/WNL.0000000000000488","volume":"82","author":"F Picard","year":"2014","unstructured":"Picard F, Makrythanasis P, Navarro V, Ishida S, de Bellescize J, Ville D, et al. DEPDC5 mutations in families presenting as autosomal dominant nocturnal frontal lobe epilepsy. Neurology. 2014;82(23):2101\u20136.","journal-title":"Neurology."},{"issue":"3","key":"610_CR43","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/acn3.722","volume":"6","author":"T Pippucci","year":"2019","unstructured":"Pippucci T, Licchetta L, Baldassari S, Marconi C, De Luise M, Myers C, et al. Contribution of ultrarare variants in mTOR pathway genes to sporadic focal epilepsies. Ann Clin Transl Neurol. 2019;6(3):475\u201385.","journal-title":"Ann Clin Transl Neurol"},{"issue":"6136","key":"610_CR44","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1126\/science.1232044","volume":"340","author":"L Bar-Peled","year":"2013","unstructured":"Bar-Peled L, Chantranupong L, Cherniack AD, Chen WW, Ottina KA, Grabiner BC, et al. A tumor suppressor complex with GAP activity for the rag GTPases that signal amino acid sufficiency to mTORC1. Science. 2013;340(6136):1100\u20136.","journal-title":"Science."},{"issue":"1","key":"610_CR45","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1177\/0883073817696814","volume":"33","author":"A Jeong","year":"2018","unstructured":"Jeong A, Wong M. Targeting the mammalian target of rapamycin for epileptic encephalopathies and malformations of cortical development. J Child Neurol. 2018;33(1):55\u201363.","journal-title":"J Child Neurol"},{"issue":"182","key":"610_CR46","doi-asserted-by":"crossref","first-page":"182ra53","DOI":"10.1126\/scitranslmed.3005271","volume":"5","author":"WE Parker","year":"2013","unstructured":"Parker WE, Orlova KA, Parker WH, Birnbaum JF, Krymskaya VP, Goncharov DA, et al. Rapamycin prevents seizures after depletion of STRADA in a rare neurodevelopmental disorder. Sci Transl Med. 2013;5(182):182ra53.","journal-title":"Sci Transl Med"},{"issue":"6","key":"610_CR47","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1097\/00004691-200212000-00004","volume":"19","author":"N Foldvary-Schaefer","year":"2002","unstructured":"Foldvary-Schaefer N. Sleep complaints and epilepsy: the role of seizures, antiepileptic drugs and sleep disorders. J Clin Neurophysiol. 2002;19(6):514\u201321.","journal-title":"J Clin Neurophysiol"},{"issue":"5","key":"610_CR48","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/sleep\/29.5.701","volume":"29","author":"L Nobili","year":"2006","unstructured":"Nobili L, Sartori I, Terzaghi M, Stefano F, Mai R, Tassi L, et al. Relationship of epileptic discharges to arousal instability and periodic leg movements in a case of nocturnal frontal lobe epilepsy: a stereo-EEG study. Sleep. 2006;29(5):701\u20134.","journal-title":"Sleep"},{"issue":"2","key":"610_CR49","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/brain\/awl322","volume":"130","author":"L Nobili","year":"2007","unstructured":"\u2022\u2022 Nobili L, Francione S, Mai R, Cardinale F, Castana L, Tassi L, et al. Surgical treatment of drug-resistant nocturnal frontal lobe epilepsy. Brain. 2007;130(2):561\u201373. The paper provides the evidence that patients with drug-resistant, disabling sleep-related seizures of frontal lobe origin should be considered for resective surgery, which may provide excellent results both on seizures and on epilepsy-related sleep disturbances.","journal-title":"Brain"},{"issue":"5","key":"610_CR50","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.eplepsyres.2014.02.016","volume":"108","author":"A Losurdo","year":"2014","unstructured":"Losurdo A, Proserpio P, Cardinale F, Gozzo F, Tassi L, Mai R, et al. Drug-resistant focal sleep related epilepsy: results and predictors of surgical outcome. Epilepsy Res. 2014;108(5):953\u201362.","journal-title":"Epilepsy Res"},{"issue":"SUPPL. 2","key":"610_CR51","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/j.sleep.2011.10.018","volume":"12","author":"P Proserpio","year":"2011","unstructured":"Proserpio P, Cossu M, Francione S, Gozzo F, Lo Russo G, Mai R, et al. Epileptic motor behaviors during sleep: anatomo-electro-clinical features. Sleep Med. 2011;12(SUPPL. 2):S33\u20138.","journal-title":"Sleep Med"},{"issue":"12","key":"610_CR52","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1111\/j.1528-1167.2009.02169.x","volume":"50","author":"L Nobili","year":"2009","unstructured":"Nobili L, Cardinale F, Magliola U, Cicolin A, Didato G, Bramerio M, et al. Taylor\u2019s focal cortical dysplasia increases the risk of sleep-related epilepsy. Epilepsia. 2009;50(12):2599\u2013604.","journal-title":"Epilepsia."},{"issue":"1","key":"610_CR53","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1212\/WNL.51.1.48","volume":"51","author":"A. Handforth","year":"1998","unstructured":"Handforth A, DeGiorgio CM, Schachter SC, Uthman BM, Naritoku DK, Tecoma ES, et al. Vagus nerve stimulation therapy for partial-onset seizures: a randomized active-control trial. Neurology. 1998;51(1):48\u201355.","journal-title":"Neurology"},{"issue":"11","key":"610_CR54","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1111\/j.1528-1167.2011.03214.x","volume":"52","author":"M Carre\u00f1o","year":"2011","unstructured":"Carre\u00f1o M, Garcia-Alvarez D, Maestro I, Fern\u00e1ndez S, Donaire A, Boget T, et al. Malignant autosomal dominant frontal lobe epilepsy with repeated episodes of status epilepticus: successful treatment with vagal nerve stimulation. Epilepsia. 2011;52(11):e168\u201371.","journal-title":"Epilepsia"},{"issue":"3","key":"610_CR55","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.eplepsyres.2010.05.006","volume":"90","author":"R Manni","year":"2010","unstructured":"Manni R, Terzaghi M. Comorbidity between epilepsy and sleep disorders. Epilepsy Res. 2010;90(3):171\u20137.","journal-title":"Epilepsy Res"},{"issue":"8","key":"610_CR56","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1212\/01.wnl.0000323927.13250.54","volume":"71","author":"BA Malow","year":"2008","unstructured":"Malow BA, Foldvary-Schaefer N, Vaughn BV, Selwa LM, Chervin RD, Weatherwax KJ, et al. Treating obstructive sleep apnea in adults with epilepsy: a randomized pilot trial. Neurology. 2008;71(8):572\u20137.","journal-title":"Neurology."},{"issue":"6","key":"610_CR57","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.sleep.2003.06.004","volume":"4","author":"BA Malow","year":"2003","unstructured":"Malow BA, Weatherwax KJ, Chervin RD, Hoban TF, Marzec ML, Martin C, et al. Identification and treatment of obstructive sleep apnea in adults and children with epilepsy: a prospective pilot study. Sleep Med. 2003;4(6):509\u201315.","journal-title":"Sleep Med"},{"issue":"11","key":"610_CR58","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/j.1528-1167.2011.03214.x","volume":"52","author":"M Vendrame","year":"2011","unstructured":"Vendrame M, Auerbach S, Loddenkemper T, Kothare S, Montouris G. Effect of continuous positive airway pressure treatment on seizure control in patients with obstructive sleep apnea and epilepsy. Epilepsia. 2011;52(11):168\u201371.","journal-title":"Epilepsia."}],"container-title":["Current Treatment Options in Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-020-0610-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11940-020-0610-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-020-0610-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T00:33:31Z","timestamp":1611880411000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11940-020-0610-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["610"],"URL":"https:\/\/doi.org\/10.1007\/s11940-020-0610-1","relation":{},"ISSN":["1092-8480","1534-3138"],"issn-type":[{"value":"1092-8480","type":"print"},{"value":"1534-3138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"30 January 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Dr. Asioli declares that he has no conflict of interest. Dr. Rossi declares that he has no conflict of interest. Dr. Bisulli declares that she has no conflict of interest. Dr. Licchetta declares that she has no conflict of interest. Dr. Tinuper reports non-financial support and other from EISAI, non-financial support and other from LIVANOVA, non-financial support and other from UCB, non-financial support and other from GW, outside the submitted work. Dr. Provini reports personal fees from Vanda Pharmaceutical, personal fees from Sanofy, personal fees from Zambon, personal fees from Fidia, personal fees from Bial, personal fees from Eisai Japan, personal fees from Italfarmaco, outside the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"1"}}